Cardiac Resynchronization Therapy
Triple-digit heat exposure may increase odds of atrial fibrillation
CHICAGO — Rising outside temperature is associated with increased likelihood for experiencing an episode of atrial fibrillation as detected by implanted cardiac devices, according to new research.
Algorithm can help optimize device therapy for patients with HFrEF
HF is associated with a fourfold increased risk for death and a sixfold to ninefold increased risk for sudden cardiac death, and its direct and indirect costs are estimated to reach $69.8 billion annually in the United States by 2030.
Novel defibrillation lead beats safety, efficacy goals
A novel lead for use in implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators exceeded the safety and efficacy thresholds in the LEADR trial, researchers reported at Heart Rhythm 2024.
Leadless permanent pacemaker implant shows favorable safety at 5 years
The 5-year rates of major complications and need for system revision were very low for patients receiving a transcatheter leadless pacemaker implant, according to real-world data published in the European Heart Journal.
Cardiac resynchronization therapy displays long-term benefits vs. ICD in HFrEF
Researchers reported extended survival and greater time until adverse events among patients with HF with reduced ejection fraction assigned to cardiac resynchronization therapy vs. implantable cardioverter defibrillator therapy.
CMS bundled payment program did not produce significant benefit in HF care
Hospital participation in the CMS Bundled Payments for Care Improvement Advanced program was not associated with significant change in quality of care metrics for patients hospitalized with HF, researchers reported.
Empagliflozin may reduce ventricular arrhythmias in patients with type 2 diabetes, ICDs
PHILADELPHIA — In the EMPA-ICD trial, patients with type 2 diabetes and an implantable cardioverter defibrillator had fewer ventricular arrhythmias at 24 weeks when assigned empagliflozin compared with placebo.
Medtronic recall of ICD, CRT-D devices designated class I
Medtronic announced a recall of all implantable cardioverter defibrillator and cardiac resynchronization therapy defibrillators manufactured after Oct. 13, 2017 with a glassed feedthrough.
FDA approves next-generation pacemakers with automatic MRI field detection sensors
Biotronik announced the FDA approved its portfolio of pacemakers and cardiac resynchronization therapy pacemakers featuring automatic MRI detection designed to streamline MRI workflow.
SOLVE-CRT: Leadless pacemaker can deliver CRT to people not suited for traditional systems
A leadless, ultrasound-based endocardial pacing system was able to deliver cardiac resynchronization therapy to patients unable to be implanted with conventional CRT devices, researchers reported.